A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial

A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial

Abstract A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-controlled phase I clinical trial (NCT01986010). However, the specificities and functional properties of V160-elicited anti...

Full description

Saved in:
Bibliographic Details
Main Authors: Leike Li, Daniel C. Freed, Yaping Liu, Fengsheng Li, Diane F. Barrett, Wei Xiong, Xiaohua Ye, Stuart P. Adler, Richard E. Rupp, Dai Wang, Ningyan Zhang, Tong-Ming Fu, Zhiqiang An
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/8407aee0085d434d8f8d2b457a78ae7d
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/8407aee0085d434d8f8d2b457a78ae7d

Similar Items